Abstract:Parkinson's disease (PD) is a chronic progressive neurodegenerative disorder symptomatically characterized by resting tremor, rigidity, bradykinesia and gait impairment. These motor deficits suffered by PD patients primarily result from selective dysfunction or loss of dopaminergic neurons of the substantia nigra pars compacta (SNpc). Most of the existing therapies for PD are based on the replacement of dopamine, which is symptomatically effective in the early stage but becomes increasingly less effective and is accompanied by serious side effects in the advanced stages of the disease. Currently, there are no strategies to slow neuronal degeneration or prevent the progression of PD. Thus, the prospect of regenerating functional dopaminergic neurons is very attractive. Over the last few decades, significant progress has been made in the development of dopaminergic regenerative strategies for curing PD. The most promising approach seems to be cell-replacement therapy (CRT) using human embryonic stem cells (ESCs) or induced pluripotent stem cells (iPSCs), which are unlimitedly available and have gained much success in preclinical trials. Despite the challenges, stem cell-based CRT will make significant steps toward the clinic in the coming decade. Alternatively, direct lineage reprogramming, especially in situ direct conversion of glia cells to induced neurons, which exhibits some advantages including no ethical concerns, no risk of neoplasia, and even no need for transplantation, has gained much attention recently. Evoking the endogenous regeneration ability of neural stem cells (NSCs) is an idyllic method of dopaminergic neuroregeneration which remains highly controversial. Here, we review many of these advances, highlighting areas and strategies that might be particularly suited to the development of regenerative approaches that restore dopaminergic function in PD. Key words: Parkinson's disease, dopaminergic neurons, embryonic stem cell, induced pluripotent stem cell, neural stem cell, direct lineage reprogramming, endogenous regeneration.

Primary cilia in Parkinson's disease: summative roles in signaling pathways, genes, defective mitochondrial function, and substantia nigra dopaminergic neurons

Primary Cilia in Parkinson’s Disease: Summative Roles in Signaling Pathways, Genes, Defective Mitochondrial Function, and Substantia Nigra Dopaminergic Neurons

Primary cilia and SHH signaling impairments in human and mouse models of Parkinson’s disease

Primary Cilia and Ciliary Signaling Pathways in Aging and Age-Related Brain Disorders.

Spatiotemporal Neurodegeneration of the Substantia Nigra and Its Connecting Cortex and Subcortex in Parkinson's Disease.

Primary cilia mediate mitochondrial stress responses to promote dopamine neuron survival in a Parkinson’s disease model

The crucial role of VPS35 and SHH in Parkinson's disease: Understanding the mechanisms behind the neurodegenerative disorder

Dendritic cells in Parkinson's disease: regulatory role and therapeutic potential

Signaling Pathways in Parkinson’s Disease: Molecular Mechanisms and Therapeutic Interventions

Parkinson's disease: From genetics to molecular dysfunction and targeted therapeutic approaches

Cell–Cell Communication Alterations Via Intercellular Signaling Pathways in Substantia Nigra of Parkinson’s Disease

Progress in Dopaminergic Cell Replacement and Regenerative Strategies for Parkinson's Disease.

Differentiation and regulation of CD4+ T cell subsets in Parkinson's disease

Comprehensive Analysis of Core Genes and Key Pathways in Parkinson's Disease

Advances in clinical basic research: Performance, treatments, and mechanisms of Parkinson disease

Intracellular and Intercellular Mitochondrial Dynamics in Parkinson's Disease

Role of the Peripheral Nervous System in PD Pathology, Diagnosis, and Treatment

Progress in dopaminergic cell-replacement and regenerative strategies for Parkinson's disease.

Loss of primary cilia and dopaminergic neuroprotection in pathogenic LRRK2-driven and idiopathic Parkinson’s disease

Molecular chaperones and Parkinson's disease

Role of Chemokines in Parkinson's Disease